Hepatocellular Carcinoma Development

As with all cancers, hepatocellular carcinoma arises as the result of genetic mutation, which leads to an abnormally high rate of cellular replication and/or causes cells to avoid programmed cell death (apoptosis). In these cells, the damaged DNA is not repaired and neither do the cells die. Instead, they multiply and give rise to increasing amounts of abnormal cells that contain the same defective DNA.

As the cancer cells proliferate, they eventually form tumors. Not all tumors are cancerous and capable of spreading. Those that are capable of spreading are referred to as malignant tumors. Benign tumors, on the other hand, do not invade other organs or spread to other parts of the body, although they can grow to a large size and start to press on surrounding organs and tissues.

Long-term infection with hepatitis B and/or hepatitis C can promote the development of hepatocellular carcinoma because the body’s immune system repeatedly launches attacks on cells in the liver because some are infected with the virus. However, this immune response can also damage healthy liver cells. During this ongoing cycle of damage and repair, mutations are eventually acquired in the DNA, which leads to the development of cancer.

In cases of chronic hepatitis C, hepatocellular cancer occurs while the liver is in the cirrhotic stage of disease, while in hepatitis B the cancer can arise during the non-cirrhotic phase. Hepatitis A and other forms of viral hepatitis do not cause chronic infections and therefore do not lead to liver cancer.

Another primary cause of hepatocellular cancer is long-term alcoholism because it leads to cirrhosis. Aflatoxin from the fungus Aspergillus is also carcinogenic and causes hepatocellular carcinoma when it accumulates in the liver. The combination of a high prevalence of aflatoxin and hepatitis B in West Africa and China means there is an increased rate of hepatocellular carcinoma in these regions.

Further Reading

Last Updated: Feb 26, 2019

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2019, February 26). Hepatocellular Carcinoma Development. News-Medical. Retrieved on July 21, 2024 from https://www.news-medical.net/health/Hepatocellular-Carcinoma-Development.aspx.

  • MLA

    Mandal, Ananya. "Hepatocellular Carcinoma Development". News-Medical. 21 July 2024. <https://www.news-medical.net/health/Hepatocellular-Carcinoma-Development.aspx>.

  • Chicago

    Mandal, Ananya. "Hepatocellular Carcinoma Development". News-Medical. https://www.news-medical.net/health/Hepatocellular-Carcinoma-Development.aspx. (accessed July 21, 2024).

  • Harvard

    Mandal, Ananya. 2019. Hepatocellular Carcinoma Development. News-Medical, viewed 21 July 2024, https://www.news-medical.net/health/Hepatocellular-Carcinoma-Development.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds key gene deletion shields mice from diet-induced obesity and liver disease